ProCE Banner Activity

Phase III Trial of First-line Ibrutinib + R-CHOP vs Placebo + R-CHOP in Patients With Non–Germinal Center B-Cell Subtypes of DLBCL

Slideset Download
Conference Coverage
EFS, PFS, and OS were prolonged among patients younger than 60 years who were treated with ibrutinib + R-CHOP vs placebo + R-CHOP.

Released: December 14, 2018

Expiration: December 13, 2019

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie

AstraZeneca

Celgene

Dova Pharmaceuticals

Gilead Text

Incyte

Janssen Biotech Pharmacyclics Abbvie

Jazz Pharmaceuticals Inc

Novartis Pharmaceuticals Corporation

Seagen

Takeda Oncology